Visualization of Asymptomatic Atherosclerotic Disease for Optimum Cardiovascular Prevention (VIPVIZA)
Research infrastructure
VIPVIZA is a population-based study in Västerbotten designed to systematically visualize early atherosclerosis and thereby support improved risk assessment and prevention of cardiovascular disease.
About VIPVIZA
VIPVIZA (“Visualization of Asymptomatic Atherosclerotic Disease for Optimum Cardiovascular Prevention”) was launched in 2013 as a large, population based randomized controlled trial with study participants recruited from Västerbotten Intervention Program (VIP). Over time, it has evolved into a comprehensive longitudinal research platform with an integrated biobank and an extensive carotid ultrasound imaging infrastructure. This unique combination of serial vascular imaging, detailed phenotyping, and long term follow up provides an exceptional opportunity to study the natural history of subclinical atherosclerosis. It enables detailed characterization of early vascular changes, identification of trajectories of atherosclerotic progression and the influence of lifestyle and psychosocial factors, as well as evaluation of their prognostic significance for future cardiovascular events.
Strategic relevance
VIPVIZA constitutes an infrastructure that brings together researchers from many different disciplines and enables the formulation of research questions that would not emerge within individual fields. The infrastructure’s high quality imaging data, long follow up, and integrated biobank make it internationally attractive and strengthen opportunities for larger research collaborations and competitive grant applications. It also functions as a training environment for the next generation of researchers by offering projects in clinical and methodological research as well as training in advanced analytical methods. VIPVIZA further enhances the faculty’s profile within translational research by integrating molecular data, imaging diagnostics, and behavioral interventions into a coherent research workflow.
The research infrastructure adds value to existing infrastructures such as NSHDS and PREDICT by providing systematic imaging of early atherosclerosis, which enables studies of biomarkers linked to objectively measured vascular changes. This also creates new opportunities for AI based multimodal prediction models that combine lifestyle factors, psychosocial variables, biomarkers, and vascular imaging. Moreover, VIPVIZA’s randomized component provides unique possibilities for causal analyses that complement other population cohorts.
What to do if you want to study on VIPVIZA data
Text...
Acronym
VIPVIZA: VIsualiZation of asymptomatic Atherosclerotic disease for optimum cardiovascular prevention. A Randomized controlled trial nested in Västerbotten Intervention Programme.